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ABSTRACT  
Objective: This study aimed to perform pharmacokinetic profile of rosmarinic acid (RA), sinensitin (SIN), eupatorin (EUP) and 3΄
Methods: An isocratic elution program consisting of methanol: tetrahydrofuran: water (0.1% H
-hydroxy-5,6,7,4΄-
tetramethoxyflavone (TMF) in Orthosiphon stamineus ethanolic extract (OS-E) and its nanoliposomes (OS-EL) after oral and intravenous 
administration in Sprague-Dawley rat’s plasma by developing and validating a high-performance liquid chromatography (HPLC) method with 
ultraviolet (UV) detection.  
3PO4
Results: The HPLC-UV method was successfully developed and validated for simultaneous determination of major chemical constituent from OS-E 
and OS-EL in rat’s plasma. The method recorded the mean recoveries from extraction were between 91.39 and 100.32%. With regards to the 
intravenous administration of OS-EL, all four marker compounds appeared to be poorly distributed and cleared slowly from the body compared to 
OS-E. Whilst in oral administration of OS-EL, the bioavailability of all marker compounds were higher than OS-E due to higher solubility of 
encapsulation in phospholipids.  
) mixture in the volume ratio 55: 5: 40 on 
Nucleosil C18 column (250 × 4.6 mm internal diameter × 5 µm particles size) was applied. The current study followed a two-ways crossover study 
design. OS-E and OS-EL were administered orally at 1000 and 500 mg/kg, respectively. They were also administered intravenously at 250 mg/kg 
via the tail vein.  
Conclusion: The higher solubility and bioavailability of OS-EL may contribute to encapsulation in phospholipids. 
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Orthosiphon stamineus (OS) Benth. (Lamiaceae) is a medicinal plant 
grown in Southeast Asia and currently cultivated in Indonesia and 
Malaysia. The local name of OS in Malaysia is Misai Kucing. The 
leaves of OS have been used traditionally in treating angiogenesis-
related diseases, urinary lithiasis, edema, inflammation, eruptive 
fever, influenza, hepatitis, jaundice, rheumatism, diabetes, and 
hypertension [1]. OS leaves are used commonly in South-east Asian 
and European countries as herbal tea, known as “Java tea”. Various 
chemical constituents including flavonoids, terpenoids, saponins, 
hexoses, organic acids, chromene, myo-inositol, and polyphenols 
have been identified in OS leaves [2]. The major caffeic acid 
derivatives present in OS is RA (fig. 1A) and 3 main flavonoids 
(lipophilic flavones) including TMF, SIN and EUP (fig. 1B-D). 
Numerous studies have reported that lipophilic flavones of OS 
possess potential therapeutic properties such as cytotoxic effect, 
diuretic, and uricosuric actions in rats [2-3]. Therefore, these 
compounds have been given considerable attention as markers of 
pharmacological activity by several researchers [4-6]. However, 
lipophilic compounds (TMF, SIN and EUP) suffer from poor 
aqueous solubility which limits OS oral bioavailability and 
therapeutic applications. Therefore, improving solubility of 
lipophilic flavones may improve bioavailability and hence the 
overall pharmacological activity of OS extracts. Liposomal drug 
delivery systems have been developed for improving solubility, 
bioavailability and efficacy, reduced toxicity, and increased 
product stability of herbal extracts [7]. 
 
Fig. 1: Chemical structure of (A) rosmarinic acid (B) 3 -́hydroxy-5,6,7,4ʹ-tetramethoxyflavone, (C) sinensetin, and (D) eupatorin 
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It is believed that drug absorption is a key component of drug 
bioavailability that determines drug’s efficacy [8]. In the lead 
optimisation phases of drug discovery, the pharmacokinetics of the 
absorbed components in blood is the key to design in vivo efficacy 
studies [9]. Thus, screening active constituents contained of herbs in 
blood is a great challenge and major obstacle for further 
pharmacological investigation. It is clear that those compounds 
which can be absorbed into the blood have the chance to show 
bioactivities. If they remain for a very short time in the body without 
maintaining an effective blood concentration, that will not be a 
material basis for efficacy [8-11].  
Quantitative analyses for in vivo pharmacokinetic application have 
been documented using either high-performance liquid 
chromatography (HPLC–UV), high-performance liquid chromate-
graphy–tandem mass spectrometry (HPLC-MS/MS), or ultra-
performance liquid chromatography/mass spectrometry (UPLC-Q-
TOF) [8-11]. To the best of our knowledge, multiple component 
levels that can be reached in plasma are very low. Therefore, 
developing a specific and sensitive method for identification and 
quantification of the active constituent of herbs in plasma is 
required.  
Several HPLC methods for analysis of the active constituent of OS 
including RA, TMF, SIN and EUP have been reported in the literature [2, 
12-13]. However, they were mainly developed to analyse the compounds 
in plant extracts but not in plasma. Moreover, the sensitivity of these 
methods, reported to be approximately 1000 ng/ml [2, 5, 13], might not 
be sufficient for their pharmacokinetic studies. Up to now, there is no 
report on pharmacokinetic properties of multiple absorbed components 
from OS-E and its nano formulation prepared by liposomes from 
soybean phospholipids (OS-EL) in the relevant literature. This 
information is crucial and vital to explore novel drug candidates further. 
Therefore, the aim of this study is to perform pharmacokinetic profile of 
multiple absorbed components such as RA, SIN, EUP, and TMF in OS-E 
and OS-EL after oral and intravenous administration in Sprague-Dawley 
rat plasma by developing and validating an HPLC method with UV 
detection.  
MATERIALS AND METHODS 
Materials 
Standardised OS-E (containing 33.95, 2.37, 5.44 and 2.64 mg/g of 
RA, TMF, SIN and EUP, respectively) and its nanoliposomes (OS-EL) 
were obtained from Department of Pharmaceutical Chemistry, 
School of Pharmaceutical Sciences, Universiti Sains Malaysia (USM). 
Preparation of standardised OS-E and OS-EL are briefly described 
here. The OS leaves were purchased from a specialised supplier of 
herbal products in Malaysia (Herbagus Trading, Kepala Batas, Pulau 
Pinang) and identified at the herbarium of School of Biological 
Sciences Universiti Sains Malaysia, where a voucher sample was 
deposited (reference number: 11009). The leaves were pulverized 
into a fine powder using milling machine (Retsch GmbH, Germany), 
and saved in air-tight plastic bags until used. In preparing the 
extract, 100 g plant powder was added to 500 ml ethanol and mixed 
continuously on a magnetic stirrer for 48 h at 50 ˚C. After cooling, 
extracts were filtered using Whatman filter paper No.1 (Whatman, 
England), concentrated at 50 °C under vacuum using a rotary 
evaporator (RE121 Buchi, Switzerland), and dried using a freeze-
drying system (Labconco, USA). The content of RA, TMF, SIN, and 
EUP in OS-E was measured using HPLC method as described by 
Siddiqui and Zhari [6].  
Liposomes of OS-E extract (OS-EL) were prepared using the film 
method as the following; soybean phospholipids was dissolved in 
chloroform and OS-E extract was dissolved in methanol, the 
solutions were mixed, and the solvent was evaporated under 
vacuum using rotary evaporator at 45 °C for 30 min, followed by 
drying in oven at 60 °C for 1 h [7].  
Characterization of OS-EL 
OS-EL was characterised for solubility, entrapment efficiency, 
Fourier transform infrared spectroscopy (FTIR), Transmission 
Electron Microscopy (TEM), and particle size and zeta potential [7]. 
Chemicals 
RA, SIN, EUP and TMF standard compounds (purity ≥ 98%) were 
purchased from Indofine (New Jersey, USA). HPLC grade methanol 
and phosphoric acid were purchased from Merck (Petaling Jaya, 
Selangor, Malaysia). Deionized water for HPLC was prepared using 
Ultra-pure water purifier system (Elgastat, Bucks, UK). Heparin was 
obtained from Sigma (Petaling Jaya, Selangor, Malaysia).  
Instrumentation 
The HPLC was performed using an Agilent Technologies series 1260 
infinity (Waldronn, Germany) system equipped with a quaternary 
pump (G 1311 C), autosampler (G 1329 B), column oven (G 1316A) 
and ultraviolet (UV) detector (G 1314 F).  
Plasma sample extraction 
In a 1.5 ml microcentrifuge tube, an aliquot of 200 µl plasma was 
added and mixed with 200 µl HPLC grade methanol. The mixture 
was vortexed for 2 min then centrifuged at 8000 rpm for 10 min. 
The supernatant was transferred into a 0.15 ml glass conical insert. 
For analysis, 20 µl of supernatant was injected into the HPLC system. 
Development and validation of HPLC method 
Chromatographic condition 
The HPLC analysis was performed according to the method 
described by Siddiqui and Zhari [6]. The chromatographic analysis 
was carried out on a Nucleosil C18 column (250 × 4.6 mm internal 
diameter × 5 µm particles size) (Macherey Nagel, Germany). The 
column temperature was maintained at 25 °C and the injection 
sample (20 µl) was eluted with an isocratic mobile phase comprising 
methanol: tetrahydrofuran: water (0.1% H3PO4
Calibration curves, linearity ranges, limit of detection (LOD) 
and limit of quantification (LOQ) 
) mixture in the 
volume ratio 55: 5: 40. Flow rate was 0.7 ml/min and detection was 
carried out at 330 nm. 
The calibration curves were constructed using six concentrations of 
the standard compounds (RA, TMF, SIN and EUP) in blank rat 
plasma samples at 0.3125, 0.625, 1.25, 2.5, 5 and 10 µg/ml. The 
calibration curves were constructed by plotting peak area against 
concentrations of each standard compound. The calibration curves 
were analysed using linear regression analysis.  
LOD and LOQ were determined by injecting successive two-fold 
dilution of the stock solutions in blank rat plasma. The LOD was 
defined as the lowest concentration that the analytical system can 
reliably differentiate from the background level. However, the LOQ 
was defined as the lowest quantifiable concentration that can be 
measured by a standard level of confidence [14].  
Within-day and between-day precisions and recovery of plasma 
extraction 
The within-day precisions were determined at six concentrations 
with six replicates each carried out on a single day, whereas the 
between-day values were obtained over six consecutive days. The 
recovery of standard compounds from plasma was determined by 
comparing the responses obtained after liquid-liquid extraction of 
standard compounds from spiked plasma with those obtained after 
the direct injection of standard compounds prepared in methanol. 
The percentage recovery was calculated using the following 
equation:  
% Recovery = [calculated concentration/theoretical concentration] × 100 
The above analysis was carried out in triplicates. 
Animals 
Male Sprague-Dawley rats weighing 350-410 g were obtained from 
the Animal Research and Service Centre (ARASC), Universiti Sains 
Malaysia, Penang, Malaysia. The animals were maintained on a 12 h 
light-dark cycle, at room temperature and were allowed free access 
to standard food pellets.  
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Ethical approval  
The study was approved by the Animal Ethics Committee of 
Universiti Sains Malaysia, Penang, Malaysia [Protocol No: USM/ 
Animal Ethics Approval/2014/(598)]. 
Pharmacokinetic study of OS-E and OS-EL 
The study was conducted based on a two-ways crossover study 
design [10]. The animals were fasted overnight with free access to 
water prior to the experimentation. The food was only allowed after 
the sampling of blood at 4 h. In the first occasion, 3 rats (group I) 
were randomised to receive 250 mg/kg of OS-E, administered 
intravenously (IV) via the tail vein. Three rats (group II) received 
1000 mg/kg of the same extract orally, and three rats (group III) 
were randomised to receive 250 mg/kg of OS-EL, administered 
intravenously via the tail vein. Three rats (group IV) received 500 
mg/kg of OS-EL orally.  
After a washout period of 2 w, the animals from group (I) were given 
1000 mg/kg of OS-E orally, whilst those from group (II) received 250 
mg/kg intravenously of OS-E, and the animals from group (III) were 
given 500 mg/kg OS-EL orally, whilst those from group (IV) received 
250 mg/kg intravenously of OS-EL. The rats were placed in animal 
restraining cages during blood collection. Blood samples of 0.4 ml 
were withdrawn from the tail vein at 0, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 12 
and 24 h after IV injection or at 0, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12 and 
24 h after oral administration. The blood samples were collected into 
microcentrifuge tubes containing 20 µl of heparin solution. All blood 
samples were centrifuged at 3000 rpm for 10 min. The resulting 
plasma samples were kept at-20 °C prior to HPLC analysis. 
Determination of pharmacokinetic parameters 
The following pharmacokinetic parameters were estimated from the 
data of IV administration: area under plasma concentration-time 
curve (AUC0→∞), elimination rate constant (Ke), biological half-life 
(t1/2), the volume of distribution (Vd), and clearance (CL). The value 
of AUC0→∞ (µg h/ml) was determined by adding the area from time 
zero to the last sampling time (AUC0→t) to the area from last 
sampling time to infinity (AUCt→∞). The Ke (h-1) was calculated using 
the relationship, t1/2=ln 2/Ke while Vd (l/kg) was calculated from the 
relationship, Vd= dose/Ke × AUC0→∞ . Clearance CL (l/kg h) was 
calculated from the relationship, CL=dose/AUC0→∞ . However, the 
area under plasma concentration-time curve AUC0→24 (µg h/ml), 
maximum concentration (Cmax) and time to reach Tmax
Statistical analysis 
 to maximum 
concentration were calculated from the data of oral administration. 
The percentage of the absolute bioavailability of the standard 
compounds was estimated from the following equation [10]. 
% Absolute bioavailability (F) = (AUC for oral/AUC for IV) a 
× (IV dose/oral dose) × 100 
The samples were analysed in triplicates and results were presented 
as mean±SEM, n = 6. The difference between pharmacokinetic 
parameters after oral and IV administration of OS-E and OS-EL was 
compared by a two-sided t-test using the Statistical Package for 
Social Sciences (SPSS, version 18.0).  
RESULTS 
Characterization of OS-EL 
OS-EL showed substantial enhancement of extract’s solubility from 
956±34 to 3979±139 μg/ml, with entrapment efficiency of 
66.2±0.9%. FTIR study indicates an interaction between soybean 
phospholipids (SPL) and OS-E extract (fig. 2). Remarkable changes 
were observed in the infrared absorption spectra as a result of 
incorporation of OS-E extract in phospholipids; the broad band 
corresponding to OH groups was shifted from 3387 cm−1 to 3421 
cm−1, the C=O bonds at 1695 cm−1 and 1607 cm−1 disappeared, the 
band corresponding to C=O stretching in phospholipids was shifted 
from 1650 cm−1 to 1634 cm−1, the band at 1267 cm−1 was shifted to 
lower frequency (1225 cm−1) with much lower oscillation strength, 
the band at 1232 cm−1 disappeared, and band at 1075 cm−1 was 
shifted to 1071 cm−1
 
. The most pronounced spectral changes can be 
observed in the spectral region corresponding to the polar heads of 
phospholipids. Such changes may represent hydrogen bonding 
between the polar heads of phospholipids with the hydroxyl groups 
in OS-E extract. Hydrogen bonding can also occur between the keto 
groups of flavonoids and oxygen groups of phospholipids. The 
hydrophobic interaction may also occur between the flavone’s 
methoxy groups and the phospholipid tails. TEM and dynamic light 
scattering show the presence of round anionic nanoliposomes with 
particle size and zeta potential of 152.5±1.1 nm and-49.8±1.0 mV, 
respectively [7] (fig. 3).  
 
Fig. 2: FTIR spectra of OS-E, SPL and OS-EL [7] 
 
Development and validation of HPLC method 
The present HPLC method was developed and validated for 
application in the pharmacokinetic study. RA, TMF, SIN and EUP 
were well-separated from potential interfering compounds in the 
plasma under the described chromatographic condition. 
Chromatographic peaks were identified with the aid of pure 
standards of RA, TMF, SIN, and EUP based on retention time. The 
chromatograms of blank rat plasma, plasma spiked with mixed 
standards of RA, TMF, SIN and EUP, and plasma samples after oral 
and IV administration of OS-E and OS-EL are illustrated in fig. 4. 
The total run time was 30 min. The linearity of detector response 
was assessed for extracted plasma samples.  
Calibration curve of standard compounds are presented in fig. 5. 
In OS-E and OS-EL, the elution profile of standard compounds in 
plasma is similar to that observed in the corresponding 
standards. 
 
Ismail et al. 
Int J Pharm Pharm Sci, Vol 9, Issue 1, 199-206 
202 
 
Fig. 3: Morphology and particle size analysis of the OS-EL. Transmission Electron Microscopy (TEM) photograph of OS-EL (A) and their 
lipid bilayer (B), particle size distribution (C), and zeta potential distribution (D). This fig. confirms the presence of round liposomes with 
narrow size distribution (<200 nm) and a negative surface charge [7] 
 
 
Fig. 4: Chromatograms from the analysis of RA (1), TMF (2), SIN (3) and EUP (4). (A) blank rat plasma; (B) rat plasma spiked with 10 
µg/ml of 1, 2, 3 and 4, respectively; (C) rat plasma at 1 h after intravenous administration of 250 mg/kg OS-E; (D) rat plasma at 4 h after 
oral administration of 1000 mg/kg OS-E; (E) rat plasma at 1 h after intravenous administration of 250 mg/kg OS-EL; (F) rat plasma at 4 h 
after oral administration of 500 mg/kg OS-EL 
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Fig. 5: Mean standard calibration curves of RA, TMF, SIN and 
EUP prepared using blank rat plasma 
 
Linearity was evaluated by determining a series of six 
concentrations of the standard solution in three replicates. Linear 
regression equations and correlation coefficients were established 
from the graph by plotting the mean of peak area versus the 
concentration. The standard solutions of the standard compounds 
showed good linearity over the evaluated concentration in the range 
of 0.3125-10 µg/ml. In addition, the correlation coefficient values 
(R2
Deproteinization with methanol gave a high percentage recovery 
ranged from 91.39% to 100.32%, with %RSD 1.04-7.85 which 
indicates the good accuracy of the method (table 2). Thus, implying 
deproteinization of the plasma with methanol did not result in any 
substantial loss of the chemical constituents. The peak area was 
applied to calculate the %RSD of the standard compounds. Within-
day and between-day precision data are shown in table 2. 
Acceptable precision was achieved with the method as the mean 
%RSD for all standard compounds is less than 6%. The validated 
results indicate that the method is reliable, repeatable, and 
reproducible.
) of all four marker compounds were greater than 0.999. The 
sensitivity of the method was evaluated by LOD and LOQ analyses 
(table 1). 
  
Table 1: Calibration data, LOD and LOQ of the reported HPLC method 
Compound LOD (µg/ml) LOQ (µg/ml) Linearity range (µg/ml) Equation  R2Value  
RA 0.11 0.29 0.3125-10 Y=27.35X-7.782 0.999 
TMF 0.13 0.41 0.3125-10 Y=37.89X+34.49 0.999 
SIN 0.11 0.36 0.3125-10 Y=49.28X+43.49 0.999 
EUP 0.13 0.42 0.3125-10 Y=42.62X+10.29 0.999 
 
Table 2: Extraction recovery, within-day and between-day precision and accuracy values (n = 6) for RA, TMF, SIN and EUP 
Name  Concentration Recovery Within Day Between day 
 (µg/ml) Mean RSD (%) Accuracy (% of true value) RSD (%) Accuracy (% of true value) RSD (%) 
RA 0.3125 98.23 1.36 98.14 0.33 98.56 1.42 
0.625 95.34 1.22 97.83 2.07 100.17 5.31 
1.25 91.39 6.97 97.54 2.76 101.01 3.59 
2.5 99.98 6.82 101.08 1.47 94.61 1.17 
5 96.67 1.64 101.23 5.06 101.93 0.96 
10 97.89 3.39 100.40 2.09 95.50 2.80 
TMF 0.3125 98.56 2.31 100.43 0.05 100.33 3.29 
0.625 93.35 3.13 98.31 2.65 96.30 2.52 
1.25 95.22 5.45 97.61 1.33 96.94 1.41 
2.5 99.12 4.06 102.93 0.91 102.65 3.40 
5 98.10 3.51 96.25 3.15 104.56 2.32 
10 98.90 1.04 97.45 0.44 102.51 3.34 
SIN 0.3125 92.04 4.03 99.20 1.58 98.72 2.79 
0.625 92.60 7.85 93.54 2.97 98.56 2.70 
1.25 93.03 3.78 97.24 1.48 102.67 1.49 
2.5 93.52 6.09 103.63 2.51 101.11 0.78 
5 94.75 2.02 97.04 0.03 100.30 4.90 
10 93.27 5.96 99.67 0.33 99.35 1.94 
EUP 0.3125 93.11 4.71 100.07 1.89 98.86 1.70 
0.625 97.10 6.13 99.78 3.09 99.22 2.61 
1.25 91.39 6.74 104.51 1.63 102.62 0.95 
2.5 99.56 4.64 100.00 1.54 100.89 1.17 
5 93.46 4.93 99.05 0.05 98.97 0.05 
10 91.50 1.59 98.74 0.79 102.07 1.85 
 
Determination and quantification of RA, TMF, SIN and EUP 
content in rat’s Plasma 
The HPLC method was applied for analyses of RA, TMF, SIN and EUP in 
rat’s plasma after oral and IV administration of OS-E and OS-EL. As 
shown in fig. 4 selected standard compounds were well separated by the 
developed HPLC method. The course of mean plasma concentration 
versus time profiles of RA, TMF, SIN, and EUP after IV and oral 
administration of OS-E and OS-EL are shown in fig. 6-7. Results were 
derived from the mean of a peak area from three replicate injections. 
Pharmacokinetic study of OS-E and OS-EL 
Following intravenous administration of OS-E and OS-EL showed a 
gradual decline in its plasma concentrations (fig. 6-7). The estimated 
volume of distribution (Vd
However, these marker compounds appeared to be cleared from the 
body in OS-EL slower than OS-E as evidenced by their smaller mean 
clearance values (table 3). In addition, marker compounds in OS-E 
showed longer half-life compared to OS-EL. This result may imply 
that the marker compound which was more distributed into the 
tissue retained in blood compartment for a longer time (table 3). 
) of the marker compounds in OS-E was 
relatively higher than OS-EL. This suggests that the marker 
compounds were more distributed into the tissue compartment in 
OS-E compared to OS-EL (table 3).  
Pharmacokinetic results of marker compounds after oral 
administration of OS-E and OS-EL are presented in table 4. An 
increase of the plasma concentration of RA, TMF, SIN and EUP was 
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observed after oral administration of the OS-E and OS-EL which may 
indicate absorption of these standard compounds into the blood. 
The standard compounds in OS-E showed relatively lower Cmax  and 
Tmax
 
 compared to OS-EL. These results indicate that standard 
compounds in OS-E extract stayed in the body for relatively shorter 
time compared to OS-EL. The AUC values of OS-EL were extremely 
larger than OS-E after oral administration, which indicates a great 
absorption and utility of the standard compounds in rat plasma. 
Similarly, oral bioavailability of marker compounds in OS-EL was 
higher than OS-E (table 4). 
 
Fig. 6: Mean plasma concentration-time profiles (mean±SEM, n=6) of RA, TMF, SIN and EUP after intravenous at 250 mg/kg (A) and oral at 
1000 mg/kg (B) administration of OS-E 
 
 
Fig. 7: Mean plasma concentration-time profiles (mean±SEM, n=6) of RA, TMF, SIN and EUP after intravenous at 250 mg/kg (A) and oral at 
500 mg/kg (B) administration of OS-EL 
 
Table 3: Pharmacokinetic parameters of RA, TMF, SIN and EUP in rat plasma after intravenous administration of OS-E and OS-EL (n=6) 
Data Unit  OS-E OS-EL 
RA TMF SIN EUP RA TMF SIN EUP 
AUC µg h/ml (24-∞) 4.13±0.15 1.68±0.27 2.32±0.10 1.73±0.02 5.30±0.26 3.93±0.37* 3.81±0.09* 4.56±0.10* * 
Ke h 0.62±0.03 -1 1.44±0.06 1.30±0.05 1.30±0.03 0.95±0.02 1.45±0.01 * 1.46±0.10 1.43±0.06 
t h 1/2 1.13±0.06 0.49±0.02 0.54±0.02 0.53±0.01 0.73±0.02 0.48±0.01 * 0.49±0.03 0.49±0.02 
V l/kg h d 1.06±0.08 0.09±0.01 0.14±0.00 0.09±0.00 0.55±0.04 0.03±0.00* 0.08±0.00* 0.03±0.00* 
CL  
* 
l/kg h 0.66±0.04 0.12±0.01 0.19±0.01 0.12±0.00 0.52±0.03 0.05±0.00* 0.12±0.00 * 0.05±0.00* 
* (P ≤ 0.05) significantly different compared with OS-E extract. 
 
Table 4: Pharmacokinetic parameters of RA, TMF, SIN and EUP in rat plasma after oral administration of OS-E and OS-EL (n=6) 
Data Unit  OS-E OS-EL 
RA TMF SIN EUP RA TMF SIN EUP 
AUC µg h/ml (0-24) 4.37±0.28 0.91±0.06 1.57±0.30 1.74±0.26 7.41±0.14 5.02±0.16* 5.80±0.17* 5.69±0.25* * 
C µg/ml max 1.89±0.07 0.77±0.05 1.06±0.12 1.29±0.15 2.56±0.10 1.96±0.06* 2.31±0.18* 2.91±0.02* 
T 
* 




% 26.45±1.42 15.28±2.55 16.86±3.13 24.95±3.49 70.64±3.87 66.26±5.95* 76.61±3.99* 81.39±2.46* *  
* (P ≤ 0.05) significantly different compared with OS-E extract. 
 
DISCUSSION 
Medicinal plant whose therapeutic efficacy is based on combined 
action of a mixture of constituents. This modulates multiple targets 
with fewer adverse effects and lower toxicity simultaneously and 
offers new treatment opportunities [15]. The medicinal plant is 
attractive for medicinal use because of having pool chemical 
compounds and natural products. Therefore, increasing attention 
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has been paid to the scientific evaluation of medicinal plants. 
Efficient detection and rapid characterization of natural products 
play key roles as an analytical support in the work of natural 
products chemists [16]. Pharmacokinetics of multi-component is 
feasible with semi-quantitative analysis based on peak area versus 
time. It also helps to reveal the potential active chemical 
constituents [17].  
OS has been traditionally used for treating urinary lithiasis, edema, 
inflammation, eruptive fever, influenza, hepatitis, jaundice, biliary, 
rheumatism, diabetes, hypertension, diuretic, and a remedy for 
kidney stones [18-20]. Chemical studies showed caffeic acid 
derivatives (RA) and three main flavonoids (lipophilic flavones) 
including SIN, TMF and EUP are the major chemical constituent of 
OS extracts [7]. However, lipophilic compounds (TMF, SIN and EUP) 
suffer from poor aqueous solubility that limits the OS oral 
bioavailability and therapeutic applications. Therefore, in this study 
improvement of solubility and bioavailability of the lipophilic 
flavones present in the OS-E extract by liposomal drug delivery 
systems (OS-EL) was studied. This is the first study on the time-
course analysis of RA, TMF, SIN, and EUP concentration after oral 
and IV administration of OS-E and OS-EL extracts in rat’s plasma.  
OS-EL showed lower Vd , half-life (t1/2
Oral administration of OS-EL indicated the slow rise of marker 
compounds. This was followed by a gradual decline to 0 after 12 h. 
However, results obtained from oral administration of OS-E showed 
a faster rise of marker compounds in comparison to OS-EL. The 
mean values of C
) and CL, higher peak 
concentration and larger AUC values for all standard compounds 
compared to OS-E after IV administration. This indicates that in OS-
E, standard compounds are able to distribute into the tissue 
compartment and remain in blood plasma relatively more than OS-
EL. However, in OS-EL, standard compounds appeared to be cleared 
from the body slower than OS-E as evidenced by their smaller mean 
clearance values. Moreover, the concentration of the marker 
compounds in OS-EL was higher than OS-E. These results revealed 
good improvement in aqueous solubility and bioavailability of 
marker compounds in OS-EL compared to OS-E extracts. 
max
A maximum plasma concentration of marker compounds was 
observed between 2.83 to 3.17 h and 4.42 to 4.67 h for OS-E and OS-
EL, respectively after oral administration. In OS-E, the dissolved 
marker compounds could penetrate the gastrointestinal tract more 
easily achieving their peak plasma concentration after 2.83 h. 
However, their absorption after oral administration was incomplete 
as evidenced by a much smaller AUC, being almost 2 times lower 
than OS-EL despite their oral doses of 2 times higher. The calculated 
absolute bioavailability values for all marker compounds in OS-E 
showed lower oral bioavailability compared to OS-EL (table 4). The 
lower oral bioavailability of marker compounds in OS-E might be 
contributed to their poor aqueous solubility causing only a small 
fraction available in dissolved form for absorption after oral 
administration. On the other hand, the higher oral bioavailability of 
marker compounds in OS-EL can be explained due to encapsulation 
in phospholipids, increased solubility, and the presence of nano 
scale liposomes, increased negativity and colloidal stability [21]. 
Previous research on anionic liposomes has shown enhancement of 
colloidal stability and absorption [22], and even with higher cellular 
uptake than neutral and cationic liposomes [23-24]. 
 for all marker compounds were significantly less 
than OS-EL (P ≤ 0.05) (table 4). 
CONCLUSION  
A simple and sensitive HPLC–UV detection method was developed 
for the simultaneous plasma determination of four marker 
compounds (RA, TMF, SIN and EUP) from OS extracts. This method 
is precise for the quantitative analysis of selected marker 
compounds. Additional advantages over other known methods 
include simple preparation of the sample, as well as low detection 
and quantification limits. The method was successfully applied in the 
pharmacokinetics study of the OS-E and OS-EL on rats. Intravenous 
administration revealed that all four marker compounds in OS-EL 
appeared to be poorly distributed. The markers cleared slowly from 
the body compared to OS-E. However, the marker compounds were 
absorbed rapidly in OS-E, following oral administration. Their 
absorption was incomplete with calculated absolute oral 
bioavailability values as indicated in table 4. Bioavailability of all 
marker compounds was higher in OS-EL oral than OS-E, due to the 
higher solubility of encapsulation in phospholipids. 
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